• Revance Releases Phase 3 Study Results for Toxin RT002

    2 days ago - By Surgical Aesthetics Magazine

    Revance Therapeutics has released SAKURA Phase 3 study data for its injectable daxibotulinumtoxinA for moderate-to-severe glabellar lines. The study included nearly 2,700 patients, who received up to three treatments and were followed for more than a year and a half. Based on investigator assessment, more than 95 percent of patients achieved a score of none or mild glabellar lines at maximum frown at week 4 after each of three treatments. The median time to return to baseline was 28 weeks. The median time to loss of none or mild wrinkle severity was 24 weeks. These results were consistent...
    Read more ...